THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
DIETARY SUPPLEMENT & NUTRACEUTICAL PROFILE CODE: [SUP-11] ID: TIP-MED-000635

Alpha-Lipoic Acid (R-Alpha-Lipoic Acid / Thioctic Acid)

Active Ingredient / Scientific Identity: Alpha-Lipoic Acid • Class: Clinical Nutrition & Nutraceutical Science • Amphiphilic (Water- and Fat-Soluble) Mitochondrial Dehydrogenase Cofactor & Universal Antioxidant

⚖️ Compare 579 Drugs
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Alpha-Lipoic Acid (R-Alpha-Lipoic Acid / Thioctic Acid) ([SUP-11] | ID: TIP-MED-000635) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/sup-11-alpha-lipoic-acid/
Generic / Entity NameAlpha-Lipoic Acid (R-Alpha-Lipoic Acid / Thioctic Acid) ([SUP-11])
Verified Indian Brands / RefFSSAI Licensed Health Supplement / Nutraceutical Formulations (RDA Compliant)
Pharmacological ClassClinical Nutrition & Nutraceutical Science • Amphiphilic (Water- and Fat-Soluble) Mitochon
Available Dosage FormsNutraceutical Supplemental Range: 100–300 mg/day (R-enantiomer has ~2x higher bioavailability than racemic R,S
Regulatory ClassificationFSSAI Nutraceutical Ingredient.
Key Warning & Review DateRARE BUT CLASSIC ENDOCRINE ADVERSE EFFECT: Insulin Autoimmune Syndrome (Hirata Disease — produces polyclonal anti-insulin aut
Reviewed: 2026-11-10
Safety Matrix:⚖️ Regulatory Framework: FSSAI Nutraceutical Ingredient.✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Alpha-Lipoic Acid (R-Alpha-Lipoic Acid / Thioctic Acid) (TIP-MED-000635, Reference Code [SUP-11]) is classified under Dietary Supplements & Nutraceuticals (FSSAI / ICMR-NIN) as a Clinical Nutrition & Nutraceutical Science • Amphiphilic (Water- and Fat-Soluble) Mitochondrial Dehydrogenase Cofactor & Universal Antioxidant. Within the Indian regulatory and compendial framework, it is governed under FSSAI Nutraceutical Ingredient..

Verified Indian Market Examples / Compendial Status:
FSSAI Licensed Health Supplement / Nutraceutical Formulations (RDA Compliant)
Nutritional & Regulatory Reference: Nutraceutical Supplemental Range: 100–300 mg/day (R-enantiomer has ~2x higher bioavailability than racemic R,S-ALA); therapeutic symptomatic diabetic sensorimotor polyneuropathy uses 600 mg/day under medical supervision. (FSSAI Nutraceutical Ingredient.).
Dosage Forms & Available Strengths:
Nutraceutical Supplemental Range: 100–300 mg/day (R-enantiomer has ~2x higher bioavailability than racemic R,S-ALA); therapeutic symptomatic diabetic sensorimotor polyneuropathy uses 600 mg/day under medical supervision.
Routes: Oral Nutritional Supplementation

Clinical Nutrition, ICMR-NIN RDA & FSSAI Nutraceutical Profile

Nutrient / Nutraceutical Identity:
Alpha-Lipoic Acid
Category:
Amphiphilic (Water- and Fat-Soluble) Mitochondrial Dehydrogenase Cofactor & Universal Antioxidant
Natural Dietary Sources (Indian Context):
Endogenous mitochondrial synthesis; trace dietary amounts in spinach, broccoli, and organ tissues

ICMR-NIN 2024 Recommended Dietary Allowance (RDA) & Tolerable Upper Intake Limit (UL): Nutraceutical Supplemental Range: 100–300 mg/day (R-enantiomer has ~2x higher bioavailability than racemic R,S-ALA); therapeutic symptomatic diabetic sensorimotor polyneuropathy uses 600 mg/day under medical supervision.

Deficiency Clinical Syndromes vs Chronic Excess / Hypervitaminosis Risks: RARE BUT CLASSIC ENDOCRINE ADVERSE EFFECT: Insulin Autoimmune Syndrome (Hirata Disease — produces polyclonal anti-insulin autoantibodies via sulfhydryl cleavage in genetically susceptible HLA-DRB1*04:06 individuals, causing spontaneous postprandial hypoglycaemia); additive blood glucose lowering with insulin/sulfonylureas.

Drug–Nutrient Chelation & Timing Interactions: Food and divalent minerals (calcium, iron, magnesium) reduce oral ALA bioavailability by 30–40% (take on an empty stomach 30 min before meals); chelates heavy metals and reduces efficacy of Cisplatin; competes with biotin at high doses.

FSSAI Health Supplement vs Therapeutic Drug Distinction: FSSAI Nutraceutical Ingredient.

3. Mechanism of Action & Pharmacodynamics

Essential disulfide cofactor for mitochondrial Pyruvate Dehydrogenase and Alpha-Ketoglutarate Dehydrogenase complexes; the alpha-lipoic acid / dihydrolipoic acid redox couple (-0.32 V) directly scavenges reactive oxygen species in both aqueous and lipid compartments and regenerates endogenous glutathione, Vitamin C, Vitamin E, and CoQ10.

4. Therapeutic Indications & Evidence-Supported Uses

  • Physiological & Biochemical Role: Essential disulfide cofactor for mitochondrial Pyruvate Dehydrogenase and Alpha-Ketoglutarate Dehydrogenase complexes; the alpha-lipoic acid / dihydrolipoic acid redox couple (-0.32 V) directly scavenges reactive oxygen species in both aqueous and lipid compartments and regenerates endogenous glutathione, Vitamin C, Vitamin E, and CoQ10.
  • Dietary Sources: Endogenous mitochondrial synthesis; trace dietary amounts in spinach, broccoli, and organ tissues
  • ICMR-NIN RDA & Upper Limits: Nutraceutical Supplemental Range: 100–300 mg/day (R-enantiomer has ~2x higher bioavailability than racemic R,S-ALA); therapeutic symptomatic diabetic sensorimotor polyneuropathy uses 600 mg/day under medical supervision.

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Nutraceutical Supplemental Range: 100–300 mg/day (R-enantiomer has ~2x higher bioavailability than racemic R,S-ALA); therapeutic symptomatic diabetic sensorimotor polyneuropathy uses 600 mg/day under medical supervision.

Administration & Meal Timing: Food and divalent minerals (calcium, iron, magnesium) reduce oral ALA bioavailability by 30–40% (take on an empty stomach 30 min before meals); chelates heavy metals and reduces efficacy of Cisplatin; competes with biotin at high doses.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Salt-form and meal-timing dependent gastrointestinal absorption; see bioavailability and drug-nutrient chelation notes (Food and divalent minerals (calcium, iron, magnesium) reduce oral ALA bioavailability by 30–40% (take on an empty stomach 30 min before meals); chelates heavy metals and reduces efficacy of Cisplatin; competes with biotin at high doses.).
Metabolism & Biotransformation:
Incorporated into cellular coenzyme pools, metalloproteins, or membrane phospholipids.
Elimination & Renal Adjustment:
Caution with magnesium, potassium, calcium, vitamin D, and high-dose vitamin C/collagen (oxalate) in Chronic Kidney Disease.
Hepatic Impairment Considerations:
Caution with fat-soluble vitamins and concentrated lipophilic extracts in hepatobiliary disease.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Supratherapeutic megadosing above the ICMR-NIN Tolerable Upper Intake Level (UL) without medical indication
  • RARE BUT CLASSIC ENDOCRINE ADVERSE EFFECT: Insulin Autoimmune Syndrome (Hirata Disease — produces polyclonal anti-insulin autoantibodies via sulfhydryl cleavage in genetically susceptible HLA-DRB1*04:06 individuals, causing spontaneous postprandial hypoglycaemia); additive blood glucose lowering with insulin/sulfonylureas.

Key Clinical Precautions: RARE BUT CLASSIC ENDOCRINE ADVERSE EFFECT: Insulin Autoimmune Syndrome (Hirata Disease — produces polyclonal anti-insulin autoantibodies via sulfhydryl cleavage in genetically susceptible HLA-DRB1*04:06 individuals, causing spontaneous postprandial hypoglycaemia); additive blood glucose lowering with insulin/sulfonylureas.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • RARE BUT CLASSIC ENDOCRINE ADVERSE EFFECT: Insulin Autoimmune Syndrome (Hirata Disease — produces polyclonal anti-insulin autoantibodies via sulfhydryl cleavage in genetically susceptible HLA-DRB1*04:06 individuals, causing spontaneous postprandial hypoglycaemia); additive blood glucose lowering with insulin/sulfonylureas.
Serious / Dose-Limiting Adverse Effects:
  • RARE BUT CLASSIC ENDOCRINE ADVERSE EFFECT: Insulin Autoimmune Syndrome (Hirata Disease — produces polyclonal anti-insulin autoantibodies via sulfhydryl cleavage in genetically susceptible HLA-DRB1*04:06 individuals, causing spontaneous postprandial hypoglycaemia); additive blood glucose lowering with insulin/sulfonylureas.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Food and divalent minerals (calcium, iron, magnesium) reduce oral ALA bioavailability by 30–40% (take on an empty stomach 30 min before meals); chelates heavy metals and reduces efficacy of Cisplatin; competes with biotin at high doses.

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Verify whether the patient requires physiological nutritional maintenance (<=1 RDA under FSSAI) or high-dose therapeutic deficiency correction (Schedule H/medical supervision), and check for multi-supplement stacking.

Pharmacist Patient Counselling Points:

  • Food and divalent minerals (calcium, iron, magnesium) reduce oral ALA bioavailability by 30–40% (take on an empty stomach 30 min before meals); chelates heavy metals and reduces efficacy of Cisplatin; competes with biotin at high doses.
  • Check all multivitamin and wellness labels to avoid accidentally doubling up on fat-soluble vitamins (A, D, E, K), iron, or zinc.
  • Health supplements support normal physiological nutrition and are NOT intended to diagnose, treat, cure, or prevent disease under Section 22 of the FSS Act, 2006.

Storage, Stability & Dispensing Safeguards: Store in a cool, dry place below 25°C away from moisture and direct sunlight; verify FSSAI License Number and Veg/Non-Veg symbol on packaging.

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: ICMR-NIN (National Institute of Nutrition) Nutrient Requirements and Recommended Dietary Allowances (RDA) for Indians (2020/2024); FSSAI (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food and Novel Food) Regulations, 2022.

Official Verification Portals: ICMR-National Institute of Nutrition (NIN) — Dietary Guidelines & Nutrient Requirements for Indians • FSSAI — Food Safety and Standards (Health Supplements and Nutraceuticals) Regulations

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/sup-11-alpha-lipoic-acid/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.